Wild-type (senile) amyloidosis other diagnostic studies: Difference between revisions
No edit summary |
|||
| Line 18: | Line 18: | ||
* The binding of [[Congo red]] [[stain]] to the deposited [[amyloid]] fibrils leads to characteristic apple-green [[birefringence]] under polarized [[light microscopy]] and an intense yellow-green [[fluorescence]] is seen when binding to [[thioflavin]]. | * The binding of [[Congo red]] [[stain]] to the deposited [[amyloid]] fibrils leads to characteristic apple-green [[birefringence]] under polarized [[light microscopy]] and an intense yellow-green [[fluorescence]] is seen when binding to [[thioflavin]]. | ||
* Precursor [[protein]] identification can be accomplished by [[immunohistochemistry]], [[Electron microscope|electron microscopy]], or [[mass spectrometry]] (preferred), depending upon institutional expertise. | * Precursor [[protein]] identification can be accomplished by [[immunohistochemistry]], [[Electron microscope|electron microscopy]], or [[mass spectrometry]] (preferred), depending upon institutional expertise. | ||
* Adjunctive laboratory tests to rule out AL include assaying for other organ dysfunction (e.g., proteinuria, alkaline phosphatase) and directly measuring the circulating light chains in plasma. | * Adjunctive [[laboratory]] [[Test|tests]] to rule out AL include assaying for other [[Organ (anatomy)|organ]] dysfunction (e.g., [[proteinuria]], [[alkaline phosphatase]]) and directly measuring the circulating [[Light chain|light chains]] in [[Blood plasma|plasma]]. | ||
* EMB is associated with risks of complications such as | *[[Endomyocardial biopsy|EMB]] is associated with risks of [[Complication (medicine)|complications]] such as: | ||
** Ventricular free-wall perforation | **[[Ventricle (heart)|Ventricular]] free-wall [[perforation]] | ||
** Arrhythmia | **[[Cardiac arrhythmia|Arrhythmia]] | ||
** Conduction abnormalities | **[[Electrical conduction system of the heart|Conduction]] abnormalities | ||
|- | |- | ||
!Genetic testing | !Genetic testing | ||
Revision as of 19:10, 20 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis other diagnostic studies |
|
FDA on Wild-type (senile) amyloidosis other diagnostic studies |
|
CDC on Wild-type (senile) amyloidosis other diagnostic studies |
|
Wild-type (senile) amyloidosis other diagnostic studies in the news |
|
Blogs on Wild-type (senile) amyloidosis other diagnostic studies |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.
Other Diagnostic Studies
Other diagnostic studies that help in diagnosing wild-type (senile) amyloidosis include histopathological analysis and genetic testing.[1]
| Other Diagnostic Studies | |
|---|---|
| Histopathological analysis |
|
| Genetic testing |
|
References
- ↑ Damy T, Deux JF, Moutereau S, Guendouz S, Mohty D, Rappeneau S, Guellich A, Hittinger L, Loric S, Lefaucheur JP, Plante-Bordeneuve V (December 2013). "Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis". Amyloid. 20 (4): 212–20. doi:10.3109/13506129.2013.825240. PMID 23964755.